Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeNo recent work listed

Mengyu Feng

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5104110117. Sources: OpenAlex.

Their work

Papers
19 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2017: 2 papers · 2018: 5 papers · 2019: 5 papers · 2020: 3 papers · 2021: 2 papers · 2022: none · 2023: 2 papers

Papers 19

  1. mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune mic… First author DOI 10.1016/j.canlet.2022.216020↗
  2. PRKRA promotes pancreatic cancer progression by upregulating MMP1 transcription via the NF-κB pathway. First author DOI 10.1016/j.heliyon.2023.e17194↗
  3. Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models. Co-author DOI 10.1158/1078-0432.ccr-19-3975↗
  4. Correction to: MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-021-02152-w↗
  5. Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer. First author DOI 10.1016/j.canlet.2020.05.003↗
  6. OLR1 Promotes Pancreatic Cancer Metastasis via Increased c-Myc Expression and Transcription of HMGA2. Co-author DOI 10.1158/1541-7786.mcr-19-0718↗
  7. Carboxypeptidase E down-regulation regulates transcriptional and epigenetic profiles in pancreatic cancer cell line: A network analysis. First author DOI 10.3233/cbm-191163↗
  8. Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination? Co-author DOI 10.1002/cam4.2384↗
  9. Integrated analysis of gene expression and methylation profiles of novel pancreatic cancer cell lines with highly metastatic activity. Co-author DOI 10.1007/s11427-018-9495-2↗
  10. Role of the microbiome in occurrence, development and treatment of pancreatic cancer. Co-author DOI 10.1186/s12943-019-1103-2↗
  11. Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer. Co-author DOI 10.1186/s13045-019-0777-7↗
  12. [The long coding RNA GSTM3TV2 acts an oncogene to promote chemoresistance in pancreatic cancer]. Co-author DOI 10.3760/cma.j.issn.0529-5815.2019.09.009↗
  13. NF-κB in pancreatic cancer: Its key role in chemoresistance. Co-author DOI 10.1016/j.canlet.2018.02.011↗
  14. Extracellular vesicles as mediators of the progression and chemoresistance of pancreatic cancer and their potential clinical applications. Co-author DOI 10.1186/s12943-017-0755-z↗
  15. Tumor microenvironment participates in metastasis of pancreatic cancer. Co-author DOI 10.1186/s12943-018-0858-1↗
  16. MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-018-0739-x↗
  17. LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer. Co-author DOI 10.1186/s13046-018-0947-4↗
  18. The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer. First author DOI 10.1016/j.canlet.2017.02.020↗
  19. PD-1/PD-L1 and immunotherapy for pancreatic cancer. Co-author DOI 10.1016/j.canlet.2017.08.006↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gang Yang · 18 shared papers, 2017–2023 · strength 1.83
  2. Taiping Zhang · 17 shared papers, 2017–2023 · strength 1.74
  3. Lei You · 16 shared papers, 2017–2023 · strength 1.54
  4. Yupei Zhao · 15 shared papers, 2017–2021 · strength 1.34
  5. Zhe Cao · 10 shared papers, 2017–2023 · strength 0.99
  6. Yueze Liu · 7 shared papers, 2019–2023 · strength 0.88
  7. Fangyu Zhao · 8 shared papers, 2019–2023 · strength 0.86
  8. Guangbing Xiong · 9 shared papers, 2017–2021 · strength 0.82
  9. Jiangdong Qiu · 4 shared papers, 2019–2023 · strength 0.58
  10. Jiangdong Qiu · 6 shared papers, 2018–2021 · strength 0.54
  11. Wenhao Luo · 3 shared papers, 2019–2023 · strength 0.37
  12. Hua Huang · 2 shared papers, 2018–2021 · strength 0.21
  13. Huanyu Wang · 2 shared papers, 2018–2019 · strength 0.19
  14. Jinshou Yang · 2 shared papers, 2019–2020 · strength 0.19
  15. Dan Su · 1 shared paper, 2023 · strength 0.18
  16. Jinxin Tao · 1 shared paper, 2023 · strength 0.18
  17. Zhile Bai · 1 shared paper, 2020 · strength 0.15
  18. Yong Cheng · 1 shared paper, 2020 · strength 0.15
  19. Jin Gu · 1 shared paper, 2021 · strength 0.11
  20. Jianchun Xiao · 1 shared paper, 2020 · strength 0.10
  21. Hao Chen · 1 shared paper, 2020 · strength 0.10
  22. Ming Cui · 1 shared paper, 2018 · strength 0.09
  23. Bo Xu Ren · 1 shared paper, 2018 · strength 0.09
  24. Yi‐Cheng Wang · 1 shared paper, 2019 · strength 0.09
  25. Chang Liu · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.